These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24016390)

  • 21. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
    Kim E; Correll CU; Mao L; Starr HL; Alphs L
    CNS Spectr; 2016 Dec; 21(6):466-477. PubMed ID: 27629292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis.
    Pilon D; Amos TB; Kamstra R; Manceur AM; El Khoury AC; Lefebvre P
    Curr Med Res Opin; 2019 Jan; 35(1):41-49. PubMed ID: 30106313
    [No Abstract]   [Full Text] [Related]  

  • 23. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia.
    Leatherman SM; Liang MH; Krystal JH; Lew RA; Valley D; Thwin SS; Rosenheck RA;
    J Nerv Ment Dis; 2014 Jan; 202(1):13-7. PubMed ID: 24375206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
    Broder MS; Bates JA; Jing Y; Hebden T; Forbes RA; Chang E
    J Med Econ; 2012; 15(1):105-11. PubMed ID: 21991926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone.
    Leal A; Rosillon D; Mehnert A; Jarema M; Remington G
    Pharmacoepidemiol Drug Saf; 2004 Nov; 13(11):811-6. PubMed ID: 15386706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
    Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
    J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.
    De Hert M; Sermon J; Geerts P; Vansteelandt K; Peuskens J; Detraux J
    CNS Drugs; 2015 Aug; 29(8):637-58. PubMed ID: 26293744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
    Joshi K; Pan X; Wang R; Yang E; Benson C
    Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE).
    Crivera C; DeSouza C; Kozma CM; Dirani RD; Mao L; Macfadden W
    BMC Psychiatry; 2011 Oct; 11():168. PubMed ID: 21999370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics.
    Remington G; Khramov I
    Prog Neuropsychopharmacol Biol Psychiatry; 2001 Feb; 25(2):363-9. PubMed ID: 11294482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
    Subotnik KL; Casaus LR; Ventura J; Luo JS; Hellemann GS; Gretchen-Doorly D; Marder S; Nuechterlein KH
    JAMA Psychiatry; 2015 Aug; 72(8):822-9. PubMed ID: 26107752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics.
    Lafeuille MH; Grittner AM; Fortier J; Muser E; Fasteneau J; Duh MS; Lefebvre P
    Am J Health Syst Pharm; 2015 Mar; 72(5):378-89. PubMed ID: 25694413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
    Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
    Bhanji NH; Chouinard G; Margolese HC
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral Antipsychotics.
    MacEwan JP; Kamat SA; Duffy RA; Seabury S; Chou JW; Legacy SN; Hartry A; Eramo A; Karson C
    Psychiatr Serv; 2016 Nov; 67(11):1183-1188. PubMed ID: 27417897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effectiveness of long-acting injectable antipsychotics versus oral antipsychotics in the maintenance treatment of outpatients with chronic schizophrenia.
    Fang SC; Liao DL; Huang CY; Hsu CC; Cheng SL; Shao YJ
    Hum Psychopharmacol; 2020 May; 35(3):e2729. PubMed ID: 32182388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
    Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H
    JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.
    Möller HJ
    Drugs; 2007; 67(11):1541-66. PubMed ID: 17661527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan.
    Su KP; Chang HC; Tsai SJ; Yen FC; Tang CH
    Value Health; 2009; 12 Suppl 3():S118-21. PubMed ID: 20586973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.